- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| Do | Guard Therapeutics International AB: Guard Therapeutics Announces Changes to the Company's Management Team | 216 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announces changes to the company's management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review... ► Artikel lesen | |
| Do | Guard Therapeutics International AB: Guard Therapeutics Provides Status Update Regarding Ongoing Strategic Review | 90 | GlobeNewswire (Europe) | Guard Therapeutics International AB (publ) ("Guard Therapeutics" or the "Company") hereby provides a status update regarding the strategic review that the Company announced through a press release on... ► Artikel lesen | |
| 15.01. | Guard Therapeutics International AB: Guard Therapeutics Partners in EU Consortium For Alport Syndrome | 350 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research... ► Artikel lesen | |
| 11.12.25 | Guard Therapeutics International AB (publ) receives observation status | 165 | GlobeNewswire | On December 4, 2025, Guard Therapeutics International AB (publ) (the "Company") issued a press release with information that the Board of Directors of the Company had resolved to commence an exploratory... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International AB: Guard Therapeutics Explores Strategic Alternatives | 142 | GlobeNewswire (Europe) | Guard Therapeutics (publ) ("Guard" or the "Company") today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying... ► Artikel lesen | |
| 04.12.25 | Guard Therapeutics International AB: Guard Therapeutics Provides Assessment of Full POINTER Study Results | 114 | GlobeNewswire (Europe) | Guard Therapeutics (public) ("Guard" or "the Company") today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery.... ► Artikel lesen | |
| 13.11.25 | Guard Therapeutics International AB Q3 Loss Narrows | 1 | RTTNews | ||
| 26.10.25 | Guard Therapeutics International AB: Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study | 443 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients... ► Artikel lesen | |
| 05.10.25 | Guard Therapeutics International AB: Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study | 177 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary... ► Artikel lesen | |
| 11.09.25 | Guard Therapeutics International AB: Guard Therapeutics announces completion of data collection in Phase 2b POINTER study | 702 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery... ► Artikel lesen | |
| 21.08.25 | Guard Therapeutics International AB: Guard Therapeutics publishes interim report January-June 2025 | 198 | GlobeNewswire (Europe) | The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study - ahead of schedule. The positive final safety review reinforces confidence in the trial... ► Artikel lesen | |
| 05.06.25 | Guard Therapeutics International AB: Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study | 212 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company's ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective... ► Artikel lesen | |
| 27.05.25 | Guard Therapeutics International AB: Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study | 251 | GlobeNewswire (Europe) | Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial... ► Artikel lesen | |
| 25.03.25 | Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study | 431 | GlobeNewswire (Europe) | Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled... ► Artikel lesen | |
| 14.03.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | 1.947 | Xetra Newsboard | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
| 10.03.25 | Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million | 374 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 27.02.25 | Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study | 268 | GlobeNewswire (Europe) | Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 51,50 | +0,04 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| GENMAB | 263,50 | +0,84 % | Genmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025 | Company Announcement Net sales of DARZALEX- in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,150 | -3,37 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| VERICEL | 30,000 | -2,60 % | Vericel Corporation: Vericel Announces Preliminary 2025 Financial Results and Business Updates | Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| MOLECULIN BIOTECH | 4,250 | +8,70 % | Moleculin Biotech: Aktionäre genehmigen Ausgabe von Optionsscheinen, lehnen Namensänderung jedoch ab | ||
| SENSEI BIOTHERAPEUTICS | 8,860 | -0,45 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,298 | +1,25 % | BioXcel Therapeutics kündigt Meilenstein- und Halteprämien für Führungskräfte an | ||
| MUSTGROW BIOLOGICS | 0,404 | 0,00 % | Lösung für Milliarden-Dollar-Problem: MustGrow Biologics validiert Geschäftsmodell - revolutionäre Meldung auch für Bayer und Corteva Agriscience | Raps ist für Kanada fast das, was Erdöl für Saudi-Arabien ist: Ein wirtschaftlicher Motor von gigantischem Ausmaß. Mit einem geschätzten Produktionswert von rund 14 Mrd. CAD im Jahr 2025 ist die gelb... ► Artikel lesen | |
| REGENXBIO | 8,900 | +1,71 % | Regenerative Medizin auf dem Vormarsch: Exosomen, Gen- und Zelltherapien als Wegbereiter neuer Heilansätze | ||
| AKEBIA | 1,138 | -2,90 % | Breaking Down Akebia Therapeutics: 4 Analysts Share Their Views | ||
| ZEVRA THERAPEUTICS | 7,200 | -1,37 % | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | ||
| FENNEC PHARMACEUTICALS | 6,600 | 0,00 % | Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors | - City of Hope to Evaluate PEDMARK- for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors - - Initiation of Study Reflects Growing Clinical Interest in Addressing... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 16,040 | -7,39 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M | SOUTH SAN FRANCISCO, Calif., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the closing of an upsized underwritten... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,500 | +0,92 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | ||
| NANOBIOTIX | 17,800 | -1,11 % | Nanobiotix S.A.: NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris | PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the "Company''), a late-stage clinical biotechnology company pioneering physics-based approaches... ► Artikel lesen |
GUARD THERAPEUTICS INTERNATIONAL AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -30,65 % bei einem Aktienkurs von 0,064 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GUARD THERAPEUTICS INTERNATIONAL AB finden Sie auf Wallstreet Online.